Your browser doesn't support javascript.
Expanding access to HIV services during the COVID-19 pandemic-Nigeria, 2020.
Boyd, Andrew T; Jahun, Ibrahim; Dirlikov, Emilio; Greby, Stacie; Odafe, Solomon; Abdulkadir, Alhassan; Odeyemi, Olugbenga; Dalhatu, Ibrahim; Ogbanufe, Obinna; Abutu, Andrew; Asaolu, Olugbenga; Bamidele, Moyosola; Onyenuobi, Chibuzor; Efuntoye, Timothy; Fagbamigbe, Johnson O; Ene, Uzoma; Fagbemi, Ayodele; Tingir, Nguhemen; Meribe, Chidozie; Ayo, Adeola; Bassey, Orji; Nnadozie, Obinna; Boyd, Mary Adetinuke; Onotu, Dennis; Gwamna, Jerry; Okoye, McPaul; Abrams, William; Alagi, Matthias; Oladipo, Ademola; Williams-Sherlock, Michelle; Bachanas, Pamela; Chun, Helen; Carpenter, Deborah; Miller, David A; Ijeoma, Ugonna; Nwaohiri, Anuli; Dakum, Patrick; Mensah, Charles O; Aliyu, Ahmad; Oyeledun, Bolanle; Okonkwo, Prosper; Oko, John O; Ikpeazu, Akudo; Aliyu, Gambo; Ellerbrock, Tedd; Swaminathan, Mahesh.
  • Boyd AT; Centers for Disease Control and Prevention, Division of Global HIV and TB, Center for Global Health, 1600 Clifton Road NE, Atlanta, GA, 30329, USA. ipo2@cdc.gov.
  • Jahun I; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
  • Dirlikov E; Centers for Disease Control and Prevention, Division of Global HIV and TB, Center for Global Health, 1600 Clifton Road NE, Atlanta, GA, 30329, USA.
  • Greby S; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
  • Odafe S; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
  • Abdulkadir A; Maryland Global Initiatives Corporation, University of Maryland School of Medicine Nigeria Program, Abuja, Federal Capital Territory, Nigeria.
  • Odeyemi O; Maryland Global Initiatives Corporation, University of Maryland School of Medicine Nigeria Program, Abuja, Federal Capital Territory, Nigeria.
  • Dalhatu I; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
  • Ogbanufe O; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
  • Abutu A; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
  • Asaolu O; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
  • Bamidele M; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
  • Onyenuobi C; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
  • Efuntoye T; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
  • Fagbamigbe JO; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
  • Ene U; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
  • Fagbemi A; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
  • Tingir N; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
  • Meribe C; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
  • Ayo A; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
  • Bassey O; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
  • Nnadozie O; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
  • Boyd MA; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
  • Onotu D; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
  • Gwamna J; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
  • Okoye M; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
  • Abrams W; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
  • Alagi M; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
  • Oladipo A; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
  • Williams-Sherlock M; Centers for Disease Control and Prevention, Division of Global HIV and TB, Center for Global Health, 1600 Clifton Road NE, Atlanta, GA, 30329, USA.
  • Bachanas P; Centers for Disease Control and Prevention, Division of Global HIV and TB, Center for Global Health, 1600 Clifton Road NE, Atlanta, GA, 30329, USA.
  • Chun H; Centers for Disease Control and Prevention, Division of Global HIV and TB, Center for Global Health, 1600 Clifton Road NE, Atlanta, GA, 30329, USA.
  • Carpenter D; Centers for Disease Control and Prevention, Division of Global HIV and TB, Center for Global Health, 1600 Clifton Road NE, Atlanta, GA, 30329, USA.
  • Miller DA; Centers for Disease Control and Prevention, Division of Global HIV and TB, Center for Global Health, 1600 Clifton Road NE, Atlanta, GA, 30329, USA.
  • Ijeoma U; Centers for Disease Control and Prevention, Division of Global HIV and TB, Center for Global Health, 1600 Clifton Road NE, Atlanta, GA, 30329, USA.
  • Nwaohiri A; Centers for Disease Control and Prevention, Division of Global HIV and TB, Center for Global Health, 1600 Clifton Road NE, Atlanta, GA, 30329, USA.
  • Dakum P; Institute of Human Virology (IHVN), Abuja, Federal Capital Territory, Nigeria.
  • Mensah CO; Institute of Human Virology (IHVN), Abuja, Federal Capital Territory, Nigeria.
  • Aliyu A; Institute of Human Virology (IHVN), Abuja, Federal Capital Territory, Nigeria.
  • Oyeledun B; Center for Integrated Health Program (CIHP), Abuja, Federal Capital Territory, Nigeria.
  • Okonkwo P; AIDS Prevention Initiative Nigeria (APIN), Abuja, Federal Capital Territory, Nigeria.
  • Oko JO; Catholic Caritas Foundation Nigeria (CCFN), Abuja, Federal Capital Territory, Nigeria.
  • Ikpeazu A; Federal Ministry of Health, Abuja, Nigeria.
  • Aliyu G; National Agency for the Control of AIDS, Abuja, Federal Capital Territory, Nigeria.
  • Ellerbrock T; Centers for Disease Control and Prevention, Division of Global HIV and TB, Center for Global Health, 1600 Clifton Road NE, Atlanta, GA, 30329, USA.
  • Swaminathan M; Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health, Abuja, Federal Capital Territory, Nigeria.
AIDS Res Ther ; 18(1): 62, 2021 09 19.
Article in English | MEDLINE | ID: covidwho-1430431
ABSTRACT

BACKGROUND:

To accelerate progress toward the UNAIDS 90-90-90 targets, US Centers for Disease Control and Prevention Nigeria country office (CDC Nigeria) initiated an Antiretroviral Treatment (ART) Surge in 2019 to identify and link 340,000 people living with HIV/AIDS (PLHIV) to ART. Coronavirus disease 2019 (COVID-19) threatened to interrupt ART Surge progress following the detection of the first case in Nigeria in February 2020. To overcome this disruption, CDC Nigeria designed and implemented adapted ART Surge strategies during February-September 2020.

METHODS:

Adapted ART Surge strategies focused on continuing expansion of HIV services while mitigating COVID-19 transmission. Key strategies included an intensified focus on community-based, rather than facility-based, HIV case-finding; immediate initiation of newly-diagnosed PLHIV on 3-month ART starter packs (first ART dispense of 3 months of ART); expansion of ART distribution through community refill sites; and broadened access to multi-month dispensing (MMD) (3-6 months ART) among PLHIV established in care. State-level weekly data reporting through an Excel-based dashboard and individual PLHIV-level data from the Nigeria National Data Repository facilitated program monitoring.

RESULTS:

During February-September 2020, the reported number of PLHIV initiating ART per month increased from 11,407 to 25,560, with the proportion found in the community increasing from 59 to 75%. The percentage of newly-identified PLHIV initiating ART with a 3-month ART starter pack increased from 60 to 98%. The percentage of on-time ART refill pick-ups increased from 89 to 100%. The percentage of PLHIV established in care receiving at least 3-month MMD increased from 77 to 93%. Among PLHIV initiating ART, 6-month retention increased from 74 to 92%.

CONCLUSIONS:

A rapid and flexible HIV program response, focused on reducing facility-based interactions while ensuring delivery of lifesaving ART, was critical in overcoming COVID-19-related service disruptions to expand access to HIV services in Nigeria during the first eight months of the pandemic. High retention on ART among PLHIV initiating treatment indicates immediate MMD in this population may be a sustainable practice. HIV program infrastructure can be leveraged and adapted to respond to the COVID-19 pandemic.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: HIV Infections / COVID-19 Type of study: Observational study Limits: Humans Country/Region as subject: Africa Language: English Journal: AIDS Res Ther Year: 2021 Document Type: Article Affiliation country: S12981-021-00385-5

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: HIV Infections / COVID-19 Type of study: Observational study Limits: Humans Country/Region as subject: Africa Language: English Journal: AIDS Res Ther Year: 2021 Document Type: Article Affiliation country: S12981-021-00385-5